Quick Answer
Aptevo Therapeutics Inc. reported R&D Expense of $14.54 million for fiscal year 2025.
Aptevo Therapeutics Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $14.54M | +1.1% |
| 2024 | $14.38M | -16.0% |
| 2023 | $17.11M | -4.3% |
| 2022 | $17.88M | -5.9% |
| 2021 | $18.99M | +6.4% |
| 2020 | $17.85M | -27.9% |
| 2019 | $24.76M | -30.0% |
| 2018 | $35.38M | +21.9% |
| 2017 | $29.02M | -0.3% |
| 2016 | $29.12M | -16.1% |
| 2015 | $34.73M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.04M | +30.3% | +21.5% |
| June 30, 2025 | $3.33M | -8.6% | -8.4% |
| March 31, 2025 | $3.63M | -3.2% | +17.1% |
| September 30, 2024 | $3.10M | -20.2% | -14.8% |
| June 30, 2024 | $3.64M | -33.3% | -2.9% |
| March 31, 2024 | $3.75M | -10.0% | -3.5% |
| September 30, 2023 | $3.89M | -13.2% | -28.8% |
| June 30, 2023 | $5.46M | +41.3% | +31.0% |
- Aptevo Therapeutics Inc. showed an increase of +1.1% in R&D Expense compared to the prior fiscal year.
- Over the 2015–2025 period, Aptevo Therapeutics Inc.’s r&d expense has declined by 58.1% (from $34.73 million to $14.54 million).
- The most recent figure is from Aptevo Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: